Lv1
10 积分 2024-02-22 加入
Primary resistance to immunotherapy in patients with a dMMR/MSI metastatic gastrointestinal cancer: who is at risk? An AGEO real-world study
7小时前
已完结
How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation
8小时前
已完结
BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer
8小时前
已完结
Biliary tract cancer
1个月前
已完结
A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer
4个月前
已完结
A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer
4个月前
已完结
皖公网安备34019202002308
